August 29, 2026
Research and educational content only. The compounds discussed are supplied strictly for Research Use Only (RUO) — not for human or veterinary use, diagnosis, or treatment. This article summarizes published, peer-reviewed research; it is not medical advice, and nothing here describes or endorses human use of any research compound.
“GLP-1” appears constantly in metabolic-research literature, often alongside terms like incretin, dual agonist, and receptor agonist that get used loosely in popular coverage. This overview defines those terms precisely and traces how a short-lived gut hormone became the template for one of the most closely studied classes of research peptides. The framing throughout is definitional and mechanistic: what these molecules are, how the underlying physiology was characterized in published work, and how the class expanded from single-target to multi-receptor designs.
An incretin is a gut-derived hormone that amplifies insulin secretion after nutrients are eaten. The concept rests on a specific observation, sometimes called the incretin effect: oral glucose triggers a substantially larger insulin response than an intravenous glucose load that produces the same blood-glucose level. The difference is attributed to hormones released from the intestine during digestion. According to StatPearls, the two principal incretin hormones — glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) — together account for an estimated 25% to 70% of the postprandial insulin response.
The two incretins come from different cells. GIP is secreted mainly by enteroendocrine K cells in the duodenum and proximal jejunum, while GLP-1 is released from L cells that are more abundant in the distal small intestine and colon. Both hormones share a defining trait: their insulin-stimulating action is glucose-dependent. Why does that matter? It means these signals promote insulin release primarily when glucose is elevated — a feature that shaped how researchers thought about the whole class.
The body releases GLP-1 from intestinal L cells after eating to coordinate the post-meal metabolic response — stimulating insulin, restraining glucagon, slowing gastric emptying, and promoting satiety. Published physiology characterizes these as coordinated actions: its best-known effect is glucose-dependent stimulation of insulin secretion from pancreatic beta cells, alongside suppression of inappropriate glucagon secretion.
There is a catch that shaped everything downstream: native GLP-1 is extremely short-lived. It is rapidly cleaved by the enzyme dipeptidyl peptidase-4 (DPP-4), giving the intact hormone a circulating half-life on the order of only one to two minutes (Baggio & Drucker, Physiological Reviews, 2007). So how do you turn a hormone that disappears in two minutes into something a laboratory can study? That fragility set the design problem the receptor-agonist class was built to solve.
The defining difference is durability: unlike native GLP-1, which the DPP-4 enzyme destroys within minutes, an agonist is a synthetic molecule engineered to activate the same receptor while resisting that degradation, so it keeps signaling for hours instead of seconds. In pharmacology, an agonist is a molecule that binds a receptor and activates it, producing a response similar to the body’s own signaling molecule — and a GLP-1 receptor agonist is one built to do exactly that at the GLP-1 receptor. As StatPearls puts it, “unlike the natural peptide hormone, synthetic GLP-1 is resistant to degradation by the dipeptidyl peptidase 4 (DPP-4) enzyme, and thus it has a longer half-life.”
Where did the first one come from? An unexpected source. Researchers in the 1990s identified exendin-4, a peptide in Gila monster (Heloderma suspectum) venom that is structurally similar to human GLP-1 but resistant to DPP-4 cleavage. A synthetic version, exenatide, became the first GLP-1 receptor agonist approved by the FDA, in 2005 — with a measured half-life of roughly 2.4 hours versus the native hormone’s few minutes. That durability difference is what defines the class.
The main single-target GLP-1 receptor agonists are exenatide, liraglutide, dulaglutide, and semaglutide — peptides that share GLP-1’s primary mechanism but differ in structure, dosing frequency, and half-life. Reported FDA approval milestones include:
Semaglutide, under the brand names Ozempic and Wegovy, is an FDA-approved human medicine. That regulatory status applies to specific pharmaceutical products; it does not extend to research-grade material, which is supplied strictly for Research Use Only.
Single-, dual-, and triple-agonists differ by how many receptors one peptide activates: a single agonist engages only the GLP-1 receptor, a dual agonist like tirzepatide adds the GIP receptor, and a triple agonist like retatrutide adds the glucagon receptor as well. The sharpest contrasts emerge when you compare retatrutide vs. tirzepatide or weigh semaglutide vs. retatrutide. The most active area of recent literature involves molecules that activate more than one receptor. The logic is straightforward: because GIP, GLP-1, and glucagon receptors govern overlapping metabolic pathways, a single peptide engineered to engage several of them may produce a broader signaling profile than a GLP-1-only agonist. Does adding receptors simply add effects, or change the picture entirely? That question is exactly where the field’s frontier now sits.
Tirzepatide is the first approved dual agonist, activating both the GIP and GLP-1 receptors. It was FDA-approved as Mounjaro for type 2 diabetes on May 13, 2022, and as Zepbound for chronic weight management on November 8, 2023. Like semaglutide, tirzepatide in its branded forms is an FDA-approved human medicine.
The next step in the design progression is the triple agonist retatrutide, an investigational once-weekly molecule that targets three receptors — GIP, GLP-1, and glucagon — in one peptide. Retatrutide is not FDA-approved; per Eli Lilly it remains in Phase 3 evaluation and is described as investigational. It should never be characterized as an approved drug or represented for human use.
The class traces a clear arc: from a fragile natural hormone with a two-minute half-life, to a venom-derived agonist that resisted degradation, to single-receptor peptides, and finally to the dual- and triple-receptor molecules consolidating multiple incretin and glucagon pathways into one engineered structure.
If you’re sourcing these compounds for laboratory research, every product we supply is Research Use Only, with its lot, purity and testing laboratory published on the product page or stated plainly as pending. Explore the research-compound library → the PureLab research-peptide catalog
All products are sold for Research Use Only and are not for human or veterinary consumption, diagnostic, or therapeutic use. Content is educational; no medical or performance claims are made or implied.
